Human Genome Sciences (HGSI) Looks Forward To A Promising Year

Biotech firm Human Genome Sciences (NASDAQ: HGSI) saw a huge run up in its stock price in Year 2009. Its stock rose by 1447% during the last 52 weeks. The firm is looking forward to an equally promising Year 2010.

Speaking with CNBC’s Mike Huckman, Human Genome CEO Tom Watkins said that the firm is planning to file for FDA approval of its lupus drug Benlysta. If approved, analysts are considering it to be a multi-billion dollar drug. The drug is likely to be put on a fast track approval system by FDA. Human Genome has collaborated with Glaxo SmithKline (NYSE: GSK) for this drug. Mr. Watkins evaded the question about a possible acquisition by Glaxo SmithKline.